

Haematologica
HAEMATOL/2020/262634
Version 4
Hemostatic alterations in COVID-19

Flora Peyvandi, Andrea Artoni, Cristina Novembrino, Stefano Aliberti, Mauro Panigada, Marco Boscarino, Roberta Gualtierotti, Federica Rossi, Roberta Palla, Ida Martinelli, Giacomo Grasselli, Francesco Blasi, and Armando Tripodi

Disclosures: FP reports personal fees from Bioverativ, Grifols, Roche, Sanofi, Sobi, Spark, and Takeda, outside the submitted work; CN reports personal fee from Instrumentation Laboratory, Roche, Bayer, Novonordisk, Sobi, outside the submitted work; SA reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, Chiesi, and INSMED, and personal fees from Astra Zeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd, and Horizon, outside the submitted work; RG reports personal fees from Biomarin and Takeda, outside the submitted work; IM reports personal fees from Bayer, Daiichi-Sankyo, Pfizer, Werfen, Grifols, Italfarmaco, outside the submitted work; RP reports personal fees from Novonordisk, outside the submitted work; GG reports personal fees from Biotest, Draeger Medical, Getinge Thermofisher and Fisher&Paykel, outside the submitted work. FB reports grants and personal fees from Astrazeneca, Chiesi, GSK, Insmmed, and Pfizer, grants from Bayer, personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis, and Zambon, outside the submitted work; AT reports speaker's fees from Werfen, Stago, Sobi. The other authors (AA, MP, MB, FR) have nothing to disclose.

Contributions: FP, AA and AT conceived the study. AA supervised blood samples and data collection. SA, MP, RG, IM, GG and FB managed patients. CN, FR and RP made testing. MB made statistical analysis. FP and AT wrote the manuscript. All the authors reviewed data and revised the manuscript.